Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline moves nearer to eltrombopag approval

GlaxoSmithKline moves nearer to eltrombopag approval

4th March 2008

GlaxoSmithKline (GSK) has moved closer to being able to offer the medical sector its short-term treatment for chronic idiopathic thrombocytopenic purpura (ITP).

The company’s announcement came as its Promacta/Revolade (eltrombopag) products were granted with priority review status yesterday, which it said was “encouraging”.

Eltrombopag is a once-daily oral investigational treatment which is used to induce the production of cells within bone marrow.

This generates platelets, which minimise bleeding incidents in chronic ITP. ITP is a disorder characterised by increased destruction or inadequate production of platelets, which can then increase the likelihood of bleeding and bruising.

Other symptoms include nosebleeds, bleeding gums, petechaie – small red or purple spots caused by broken capillary blood vessels – and, in more serious cases, intrecereebral or subarachnoid haemorrhage.

Dr Paulo Paletti, senior vice-president of GSK’s oncology medicine development centre, said the company’s aim is to make eltrombopag an oral solution for increasing platelets without immune system suppression.

A submission for the drug’s approval in Europe is planned by GSK. Eltrombopag would be known as Revolade in this region.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.